These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 2957187)

  • 21. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative post-antibiotic effect of five antibiotics against ten aerobic gram-positive cocci.
    Drabu YJ; Blakemore PH
    Drugs Exp Clin Res; 1990; 16(11):557-63. PubMed ID: 2151661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.
    Robbins MJ; Marais R; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1987; 13(9):551-4. PubMed ID: 2962846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities.
    Babalola CP; Patel KB; Nightingale CH; Nicolau DP
    Int J Antimicrob Agents; 2004 Apr; 23(4):343-8. PubMed ID: 15081082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
    Nashev D; Toshkova K; Gavrilova V
    Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
    Goldstein BP; Jones RN; Fritsche TR; Biedenbach DJ
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):83-7. PubMed ID: 16458124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters.
    Simon VC; Simon M
    Scand J Infect Dis Suppl; 1990; 72():14-9. PubMed ID: 2151061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse effect of staphylococci slime on in vitro activity of glycopeptides.
    Mathur T; Singhal S; Khan S; Upadhyay D; Fatma T; Rattan A
    Jpn J Infect Dis; 2005 Dec; 58(6):353-7. PubMed ID: 16377866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
    Jones RN; Sader HS; Fritsche TR; Hogan PA; Sheehan DJ
    J Clin Microbiol; 2006 Jul; 44(7):2622-5. PubMed ID: 16825398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial activity of teicoplanin against Clostridium difficile.
    Wongwanich S; Kusum M; Phan-Urai R
    Southeast Asian J Trop Med Public Health; 1996 Sep; 27(3):606-9. PubMed ID: 9185278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D; Mildvan D; Handwerger S
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility of gram positive cocci to teicoplanin. Three year survey (1984-1986) at Perugia University.
    Pasticci MB; Baldelli F; Moretti A; Menichetti F; Pauluzzi S
    Boll Ist Sieroter Milan; 1989; 68(1):5-6. PubMed ID: 2535245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of LY 333328 against anaerobic gram-positive bacteria.
    Sillerström E; Wahlund E; Nord CE
    J Chemother; 1999 Apr; 11(2):90-2. PubMed ID: 10326737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and study of antibacterial activities of antibacterial glycopeptide antibiotics conjugated with benzoxaboroles.
    Printsevskaya SS; Reznikova MI; Korolev AM; Lapa GB; Olsufyeva EN; Preobrazhenskaya MN; Plattner JJ; Zhang YK
    Future Med Chem; 2013 Apr; 5(6):641-52. PubMed ID: 23617428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
    Kenny MT; Dulworth JK; Brackman MA
    Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycopeptide tolerance in bacteria causing endocarditis.
    Perry JD; Jones AL; Gould FK
    J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
    Chisari G
    Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.